埃瓦特兰 (埃普莱伦对脏移植患者血管病变的演变的影响):跨越随机对照试验的研究协议
Arnaud Simon1, Nicolas Girerd2, Frédéric Jaisser2,3
1Nephrology Department, University Hospital of Nancy, Vandoeuvre Les Nancy, France.
Trials
|November 7, 2025
概括
矿物质皮质类受体 (MR) 抗剂治疗可以减少移植 (KT) 患者的动脉硬性. 这项研究研究了eplerenone.
科学领域:
- 腎科和移植醫學 腎科和移植醫學
- 心血管研究研究心血管研究
- 药理学 药理学是指药理学的学科.
背景情况:
- 动脉硬是接受移植 (KT) 患者心血管事件的重要预测因素.
- 在KT患者中常见的氨酸抑制剂 (CNIs) 的血管毒性与矿物质皮质醇受体 (MR) 激活有关.
- 在一般人群中,MR在动脉硬性中的作用已经得到证实.
研究的目的:
- 评估MR抗体治疗对接受环素的KT患者动脉硬性进展的影响.
- 评估eplerenone在缓解CNI诱导的血管毒性的有效性.
主要方法:
- 一个随机的,开放的,交叉试验,涉及36名稳定的CKT患者接受环素治疗.
- 参与者每天接受50毫克的eplerenone,持续6个月,然后是洗期,然后是没有治疗的6个月 (或反之亦然).
- 主要结局:eplerenone治疗6个月后脉冲波速率 (PWV) 的变化.
主要成果:
- 该研究评估了动脉硬度 (PWV) 的变化作为主要结局.
- 二次结局包括血压,内心介质厚度,左心室质量,氧化应激标志物,内皮功能和功能.
- 安全性监测包括高血症和急性功能衰竭的发生率.
结论:
- 矿物甲基皮质类受体阻塞提供了一种潜在的策略,以减少与CNI相关的血管毒性.
- 这种方法可能有助于减轻脏移植接受者的心血管风险.
- 埃普莱伦对动脉硬度的影响需要在这个患者群体中进一步研究.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
902
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
902
01:30Acute Kidney Injury IV: Diagnostic Studies and Prevention
254
Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
254
01:28Kidney Transplant I: Introduction
315
A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
315
01:22Heart Failure Drugs: Diuretics
779
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
779
01:25Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
200
In patients with renal disease, dosage adjustments are necessary to maintain therapeutic plasma drug concentrations and prevent toxicity or subtherapeutic exposure. Renal impairment alters drug pharmacokinetics, especially in conditions like uremia, where changes such as prolonged elimination half-life and altered apparent volume of distribution can significantly affect drug disposition. These changes require careful modification of the dosing regimen to achieve the desired clinical...
200
01:28Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
178
Glomerular filtration rate (GFR) can be estimated from serum creatinine using the modification of diet in renal disease (MDRD) formula or the chronic kidney disease–epidemiology collaboration (CKD–EPI) equation. Both methods are widely used in clinical practice to assess kidney function and guide treatment decisions.The MDRD equation does not require weight or height measurements and is normalized to the body surface area of 1.73 m², considered the average adult surface area.
178